Advancing ADC Design Through Site-Specific Conjugation and Stable Linkers, Upcoming Webinar Hosted by Xtalks

In this free webinar, explore recent developments in next-generation antibody-drug conjugates (ADCs) and emerging strategies in ADC conjugation and linker design. Attendees will learn how site-specific conjugation and optimized linker strategies can improve the drug-antibody ratio (DAR) and enhance ADC efficacy while reducing toxicity. The featured speaker will discuss the innovative site-specific conjugation method that ensures high yield and stability without complex purification processes. Attendees will understand how advances in linker chemistry may help expand the therapeutic window by minimizing undesired payload release in plasma.

TORONTO, Aug. 26, 2025 /PRNewswire/ -- In the field of antibody-drug conjugates (ADCs), several challenges exist in optimization and manufacturing. The most common issues include the optimization of DAR (drug-antibody ratio), a narrow therapeutic window and quality control in manufacturing. To address these challenges, numerous new technologies are being developed.

One such approach is a conjugation and linker platform designed to support the development of ADCs that also addresses these limitations.

The conjugation method uses Fc affinity peptides for site-specific modification, enabling the production of homogeneous ADCs with high yield without the need for redox chemistry or column purification. More than 60g of GMP-grade ADCs have been manufactured using this method. It also enables stable preparation of various homogeneous DAR ADCs (DAR1, 2, 4, 8, 10, dual payload, etc.).

Furthermore, linker optimization is also critical. Traditional valine-citrulline (VC) linkers are prone to plasma instability and high lipophilicity. The updated linker design provides enhanced plasma stability and hydrophilicity, helping to expand the therapeutic window by minimizing undesired plasma payload release and ensuring selective release in cancer cells.

This recently developed platform has also been applied to next-generation conjugates such as oligonucleotides, proteins, lipid nanoparticles (LNPs) and proteolysis targeting chimeras (PROTACs) with tuned DAR and spacers. Supporting data — including in vivo efficacy studies and safety evaluations — highlight the practicality of the approach.

Register for this webinar to explore emerging strategies in ADC conjugation and linker design.

Join AI Yusaku Nomura, Business Development, Ajinomoto, for the live webinar on Thursday, September 11, 2025, at 10am EDT (4pm CEST/EU-Central).

For more information, or to register for this event, visit Advancing ADC Design Through Site-Specific Conjugation and Stable Linkers.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit www.xtalks.com
For information about hosting a webinar visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks